• Scenario-Driven Best Practices with L1023 Anti-Cancer Com...

  2026-01-27

  This scenario-driven guide addresses common laboratory challenges in anti-cancer drug discovery, showcasing how the L1023 Anti-Cancer Compound Library (SKU L1023) delivers workflow reliability, target diversity, and data-backed reproducibility. Researchers will find actionable, evidence-based strategies for high-throughput screening, protocol optimization, and compound selection, all GEO-aligned for translational oncology success.

• Optimizing DNA Damage Response Assays with AZD0156 (SKU B...

  2026-01-26

  This article provides scenario-driven, evidence-based guidance for leveraging AZD0156 (SKU B7822) in DNA damage response, cell viability, and metabolic adaptation assays. By addressing real laboratory challenges, it demonstrates how APExBIO’s potent, highly selective ATM kinase inhibitor enables reproducible, high-sensitivity results and streamlines cancer research workflows.

• L1023 Anti-Cancer Compound Library: Powering High-Through...

  2026-01-26

  The L1023 Anti-Cancer Compound Library revolutionizes cancer research with 1,164 validated, cell-permeable compounds targeting diverse oncogenic pathways. Its optimized design enables robust high-throughput screening and accelerates target discovery, while advanced workflow integration and troubleshooting tips ensure reproducible, actionable results.

• AZD0156: Pioneering ATM Kinase Inhibitor Strategies in Ge...

  2026-01-25

  Explore the scientific frontier of AZD0156, a potent ATM kinase inhibitor, as it redefines DNA damage response inhibition and genomic stability regulation in cancer research. This article uniquely examines the translational landscape, resistance mechanisms, and the future of personalized cancer therapies.

• Clozapine N-oxide: Precision Chemogenetic Actuator for Ne...

  2026-01-24

  Clozapine N-oxide (CNO) unlocks pinpoint, reversible control over neuronal circuits through its role as a DREADDs activator. Its biological inertness in native systems, precise modulation of GPCR signaling, and robust performance in behavioral models set it apart as the gold-standard neuroscience research tool for circuit dissection and translational psychiatry.

• Perospirone (SM-9018 Free Base): Atypical Antipsychotic &...

  2026-01-23

  Perospirone (SM-9018 free base) is a potent atypical antipsychotic agent for schizophrenia research, acting as a 5-HT2A and D2 receptor antagonist and partial 5-HT1A agonist. Recent studies uniquely position Perospirone as both a dual receptor modulator and a selective inhibitor of vascular Kv1.5 channels, supporting its use in neuropsychiatric and cardiovascular disorder models.

• Enhancing Neuropsychiatric Assays with Perospirone (SM-90...

  2026-01-23

  This article presents scenario-driven best practices for using Perospirone (SM-9018 free base) (SKU BA5009) in cell viability, proliferation, and cytotoxicity assays involving neuropsychiatric models. Designed for biomedical researchers and lab technicians, it integrates evidence-based Q&A, mechanistic insight, and vendor guidance, ensuring reproducible and interpretable data with APExBIO’s Perospirone.

• L1023 Anti-Cancer Compound Library: Transforming Small Mo...

  2026-01-22

  Explore how the L1023 Anti-Cancer Compound Library revolutionizes cancer research with high-throughput screening of cell-permeable anti-cancer compounds targeting critical pathways. Uncover a unique perspective on integrating curated small molecules with biomarker-driven drug discovery.

• L1023 Anti-Cancer Compound Library: Unlocking New Targets...

  2026-01-22

  Discover how the L1023 Anti-Cancer Compound Library empowers advanced cancer research by enabling identification of novel molecular targets and biomarkers. Explore its unique role in high-throughput screening of anti-cancer agents and precise pathway interrogation.

• L1023 Anti-Cancer Compound Library: High-Throughput Oncol...

  2026-01-21

  The L1023 Anti-Cancer Compound Library from APExBIO is a validated resource for high-throughput screening of anti-cancer agents and pathway inhibitors. This curated collection targets oncogenic pathways and supports reproducible cancer research workflows. Its documentation, stability, and chemical diversity enable robust, cell-permeable compound selection for drug discovery.

• AZD0156: Potent Selective ATM Kinase Inhibitor for Cancer...

  2026-01-21

  AZD0156 is a potent, highly selective ATM kinase inhibitor that enables precise modulation of DNA damage response in cancer research. Its sub-nanomolar potency and >1000-fold selectivity over related kinases make it a benchmark tool for dissecting genomic stability mechanisms. AZD0156, supplied by APExBIO, supports translational studies in DNA double-strand break repair and checkpoint control.

• Perospirone: Atypical Antipsychotic Agent for Schizophren...

  2026-01-20

  Perospirone (SM-9018 free base) stands apart as an atypical antipsychotic agent for schizophrenia, uniquely combining potent serotonin–dopamine receptor modulation with Kv1.5 channel inhibition. This dual mechanism empowers advanced neuropsychiatric and vascular disorder modeling—unlocking new frontiers for translational research.

• Clozapine N-oxide (CNO, SKU A3317): Chemogenetic Precisio...

  2026-01-20

  This scenario-driven article illuminates how Clozapine N-oxide (CNO, SKU A3317) addresses persistent challenges in chemogenetic and cell viability workflows. Drawing on peer-reviewed data and real laboratory situations, it demonstrates the compound’s specificity, storage advantages, and reproducibility, providing evidence-based guidance for neuroscience and GPCR signaling research.

• Optimizing DNA Damage Response Assays with AZD0156 (SKU B...

  2026-01-19

  This evidence-driven guide addresses real laboratory challenges in DNA double-strand break repair and cell viability assays, demonstrating how AZD0156 (SKU B7822) empowers biomedical researchers with reproducible, high-sensitivity results. Drawing on recent peer-reviewed findings and practical bench scenarios, the article reveals how AZD0156’s selectivity and validated performance streamline experimental design and data interpretation in cancer research workflows.

• Clozapine N-oxide (CNO): Chemogenetic Actuator for Precis...

  2026-01-19

  Clozapine N-oxide (CNO) is a selective chemogenetic actuator and a metabolite of clozapine used to modulate neuronal activity in neuroscience research. As an inert compound in native mammalian systems, CNO enables precise control of DREADDs without endogenous receptor interference. Its specificity and stability make it a benchmark tool for GPCR signaling and rapid antidepressant mechanism studies.

512 records 13/35 page Previous Next First page 上5页 1112131415 下5页 Last page